122 results on '"Kuball, Jürgen"'
Search Results
2. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion (DLI) 2.0
3. GoCART
4. Long-term outcomes and renal responses following autologous hematopoietic stem cell transplantation for light chain deposition disease: a retrospective study on behalf of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation
5. BEHAV3D: a 3D live imaging platform for comprehensive analysis of engineered T cell behavior and tumor response
6. Allogeneic hematopoietic cell transplantation for VEXAS syndrome: results of a multicenter study of the EBMT
7. Efficacy and safety of daratumumab in pure red cell aplasia after allogeneic transplantation: Dutch real-world data
8. Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT
9. Lymphodepletion – an essential but undervalued part of the chimeric antigen receptor T-cell therapy cycle
10. Dual targeting of cancer metabolome and stress antigens affects transcriptomic heterogeneity and efficacy of engineered T cells
11. Cord blood transplantation for AML: Comparable LFS in patients with de novo versus secondary AML in CR1, an ALWP/EBMT study
12. Basics of Advanced Therapy Medicinal Product Development in Academic Pharma and The Role of a GMP Simulation Unit
13. CRISPR screens decode cancer cell pathways that trigger γδ T cell detection
14. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT
15. Graft engineering: how long can you wait, how low can you go, and pandemic readiness
16. Delayed Transfer of Immune Cells or the Art of Donor Lymphocyte Infusion
17. Clinical and Biological Concepts for Mastering Immune Reconstitution After HSCT: Toward Practical Guidelines and Greater Harmonization
18. Supplementary Table 1-4, Supplementary Figures 1-3 from An Integrative Scoring System for Survival Prediction Following Umbilical Cord Blood Transplantation in Acute Leukemia
19. Supplementary Figures 1-3 from Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
20. Supplementary Figures 1-3 from Untouched GMP-Ready Purified Engineered Immune Cells to Treat Cancer
21. The making of multivalent gamma delta TCR anti-CD3 bispecific T cell engagers
22. Comparison of Outcomes after Unrelated Double-Unit Cord Blood and Haploidentical Peripheral Blood Stem Cell Transplantation in Adults with Acute Myelogenous Leukemia: A Study on Behalf of Eurocord and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
23. Autopsy Study Defines Composition and Dynamics of the HIV-1 Reservoir after Allogeneic Hematopoietic Stem Cell Transplantation with CCR5Δ32/Δ32 Donor Cells
24. P-277: Carfilzomib, lenalidomide and dexamethasone followed by a second autologous hematopoietic cell transplantation is an effective strategy in first-relapsed multiple myeloma
25. Uncovering the mode of action of engineered T cells in patient cancer organoids
26. γ9δ2 T-Cell Expansion and Phenotypic Profile Are Reflected in the CDR3δ Repertoire of Healthy Adults
27. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial
28. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT
29. Correction to: Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
30. Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure
31. The Role of γδ T Cells as a Line of Defense in Viral Infections after Allogeneic Stem Cell Transplantation: Opportunities and Challenges
32. Association between cardiovascular risk factors and intracranial hemorrhage in patients with acute leukemia
33. Vaccine Responses in Adult Hematopoietic Stem Cell Transplant Recipients: A Comprehensive Review
34. Impact of donor-derived CD34 + infused cell dose on outcomes of patients undergoing allo-HCT following reduced intensity regimen for myelofibrosis: a study from the Chronic Malignancies Working Party of the EBMT
35. Defining the impact of SARS-COV-2 on delivery of CAR T-cell therapy in Europe: a retrospective survey from the CTIWP of the EBMT
36. Gamma delta TCR anti-CD3 bispecific molecules (GABs) as novel immunotherapeutic compounds
37. Adding Help to an HLA-A*24:02 Tumor-Reactive γδTCR Increases Tumor Control
38. Characterization and modulation of anti-αβTCR antibodies and their respective binding sites at the βTCR chain to enrich engineered T cells
39. Predictive factors for vaccine failure to guide vaccination in allogeneic hematopoietic stem cell transplant recipients
40. Anti-thymocyte globulin with CsA and MMF as GVHD prophylaxis in nonmyeloablative HLA-mismatched allogeneic HCT
41. Allogeneic Stem Cell Transplantation Platforms With Ex Vivo and In Vivo Immune Manipulations: Count and Adjust
42. Challenges of γ9δ2TCR affinity maturation when using phage display
43. Behavioral-transcriptomic landscape of engineered T cells targeting human cancer organoids
44. Allogeneic hematopoietic cell transplantation with cord blood versus mismatched unrelated donor with post-transplant cyclophosphamide in acute myeloid leukemia
45. Comparing outcomes of a second allogeneic hematopoietic cell transplant using HLA-matched unrelated versus T-cell replete haploidentical donors in relapsed acute lymphoblastic leukemia: a study of the Acute Leukemia Working Party of EBMT
46. Tumor-reactivity of δ2 negative γδT cells and the role of the γδT cell receptor
47. Defining the Role of Donor Lymphocyte Infusion in High-Risk Hematologic Malignancies
48. Inferior Outcome of Addition of the Aminopeptidase Inhibitor Tosedostat to Standard Intensive Treatment for Elderly Patients with AML and High Risk MDS
49. Cell-density independent increased lymphocyte production and loss rates post-autologous HSCT
50. Enhancing cancer targeting of γ9δ2TCR through modified NKG2D co-stimulation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.